A Phase 2 interventional study of JYB1904 and JYB1904 in Perennial Allergic Rhinitis, sponsored by Jemincare. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by Jemincare · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase II Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Patients With Perennial Allergic Rhinitis.
This study is a randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of JYB1904 injection compared to placebo in patients with PAR.
178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.
This study's planned enrollment of 135 is close to the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.
Browse Rhinitis, Allergic, Perennial studies →Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JYB1904 will be administered SC.
Biological: JYB1904
300mg JYB1904 will be administered as a subcutaneous (SC) injection.
Biological: JYB1904
Placebo will be administered SC.
Biological: Placebo+JYB1904
Double-blind Induction Period: 150mg -450mg JYB1904 will be administered SC in Day1, Week 8 and Week 16. Open-label Treatment Period: 300mg JYB1904 will be administered SC every 12 weeks (Q12W) from Week 24 to Week 48.
Double-blind Induction Period: 300mg JYB1904 will be administered SC in Day1 and Week 12. Open-label Treatment Period: 300mg JYB1904 will be administered SC Q12W from Week 24 to Week 48.
Double-blind Induction Period: Placebo will be administered SC in Day1, Week 8, Week 12 and Week16. Open-label Treatment Period: 300mg JYB1904 will be administered SC Q12W from Week 24 to Week 48.
Change from Baseline in Reflective Total Nasal Symptom Score (rTNSS) at Week 8 (JYB1904 Q8W vs Placebo) or Week 12 (JYB1904 Q12W vs Placebo)
rTNSS was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.
Time frame: baseline, Week 8, Week 12
Change from Baseline in rTNSS at Each Visit
rTNSS was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.
Time frame: up to Week 60
Change from baseline in Rhinoconjunctivitis Quality of Life Questionnaire Standardized Version [RQLQ(S)] at each Visit
The Rhinoconjunctivitis Quality of Life Questionnaire Standardized Version comprises 28 items that are grouped into 7 domains, each item was scored on a scale of 0 = Not troubled, 1 = Hardly troubled at all, 2 = Somewhat troubled, 3 = Moderately troubled, 4 = Quite a bit troubled, 5 = Very troubled, 6 = Extremely troubled. RQLQ(S) total mean scores will be calculated, with a range from 0 to 6. The higher the score was, the more serious the impact on the patient's life.
Time frame: up to Week 60
Number of days with controlled symptoms up to Week 8 (JYB1904 Q8W vs Placebo) or Week 12 (JYB1904 Q12W vs Placebo)
Controlled symptoms defined as rTNSS ≤4 with each individual item score ≤1. rTNSS was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.
Time frame: up to Week 8 or Week 12
Number of days with controlled symptoms up to Week 24
Time frame: up to Week 24
Proportion of participants requiring rescue therapy at each visit up to Week 24
Time frame: up to Week 24
Proportion of participants with ≥30% reduction from baseline in rTNSS at each visit up to Week 24
Time frame: up to Week 24
Proportion of participants with ≥50% reduction from baseline in rTNSS at each visit up to Week 24
Time frame: up to Week 24
Change from Baseline in total ocular symptom score (TOSS) at each Visit
TOSS is the sum of two symptom scores for itchy/red eyes and watery eyes, where each symptom is scored on a scale of 0 to 3. The higher the score was, the more severe the symptoms were.
Time frame: up to Week 24
Change from baseline in AR overall control Visual Analog Scale (VAS) at each visit
The VAS, in which the participant rates the degree of bother caused by AR symptoms over the past 7 days on a 100 mm-long horizontal line, where 0 mm = no bother and 100 mm = extreme bother.
Time frame: up to Week 24
Adverse Events(AEs) and Serious Adverse Events (SAEs)
Incidence and features of AEs and SAEs assessed by CTCAE v5.0, and related safety parameters analysis
Time frame: Through study completion, an average of 72 weeks
Pharmacokinetic (PK) profile of JYB1904 injection
Serum concentration of JYB1904
Time frame: Through study completion, an average of 72 weeks
Pharmacodynamic (PD) profile of JYB1904 injection
PD parameters: Changes in serum level of total and free IgE
Time frame: Through study completion, an average of 72 weeks
Immunogenicity of JYB1904 injection
Immunogenicity parameters: Positive detection rate of anti-drug antibodies (ADA)/neutralizing ADA (Nab)
Time frame: Through study completion, an average of 72 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Oct 2027, 18 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ozureprubart
Rhinitis, Allergic, Perennial →